search
Q901
Trends
- 1Qurient's CDK7 Inhibitor Q901 Shows Synergy with ADCs in Science Advances▼Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
South Korean biotech Qurient announced that its research has been published in Science Advances, showing that its selective CDK7 inhibitor Q901 works synergistically with TOP1 inhibitor-based antibody-drug conjugates. The finding supports combining Q901 with established cancer treatments and may strengthen the company's position in oncology drug development, drawing attention from investors and the biomedical research community.